Aileron Therapeutics Inc (ALRN) Stock
ALRN is no longer traded. Aileron Therapeutics was delisted from the Nasdaq in January 2025.
Prices on this page are historical; the last trade was January 10, 2025 at $2.11.
Aileron Therapeutics stock price history
ALRN final trading statistics
- Final close
- $2.11
- Final trading day
- Jan 10, 2025
- Market cap at delisting
- $45.72M
- Shares outstanding
- 21.67M
- Final 52-week range
- $1.61 – $7.42
- Avg. volume (final 3 mo.)
- 100,202
- All-time high (split-adj.)
- $298.20 · Oct 2017
- All-time low (split-adj.)
- $1.15 · Nov 2023
- Return since IPO
- -99.0%
- Beta
- 2.34
- Book value / share
- $1.41
- Price / book
- 1.50
Aileron Therapeutics annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $0.00 | -$15.7M | -$3.38 |
| FY2022 | $0.00 | -$27.0M | -$6.02 |
| FY2021 | $0.00 | -$25.8M | -$5.80 |
| FY2020 | $0.00 | -$21.8M | -$12.60 |
| FY2019 | $0.00 | -$28.8M | -$25.80 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Austin, Texas.
Aileron Therapeutics stock FAQ
What happened to Aileron Therapeutics stock?
Aileron Therapeutics stock was delisted from the Nasdaq. Its final close was $2.11 on January 10, 2025.
Is ALRN stock still trading?
No. ALRN was delisted from the Nasdaq in January 2025 and no longer trades on a U.S. exchange.
What was the last price of ALRN stock?
ALRN closed at $2.11 on its final trading day, January 10, 2025, for a market value of about $45.72M.
What were Aileron Therapeutics's revenue and earnings in its last full fiscal year?
Aileron Therapeutics reported revenue of $0.00 and net income of -$15.7M in fiscal 2023, its last full year as a public company.
When did Aileron Therapeutics go public?
Aileron Therapeutics Inc stock began trading on June 29, 2017.